uniQure(US:QURE) TMX Newsfile·2026-03-04 14:36Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the progress of its clinical trials, particularly concerning its lead product candidate AMT-130 for Huntington's disease [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired uniQure securities between September 24, 2025, and October 31, 2025 [1][2]. - Investors have until April 13, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Company Background - uniQure is a biotechnology company based in Amsterdam, focusing on gene therapies for rare and severe diseases [2]. - The company's lead product candidate, AMT-130, is currently in clinical trials for Huntington's disease [2]. Group 3: Allegations and Market Impact - The complaint alleges that uniQure misled investors about the design and progress of the Pivotal Study, creating an impression that accelerated approval was likely [3]. - Following the announcement of positive topline results on September 24, 2025, uniQure's shares surged nearly 250% in a single trading session [3]. - On November 3, 2025, the company disclosed that the FDA did not accept the Phase I/II study data for a BLA submission, resulting in a nearly 50% drop in share price from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [4].